Artemisia annua L. hot-water extracts show potent activity in vitro against Covid-19 variants including delta

1
Article URL: https://biomarket.jp/pubmed/covid-19/artemisia-annua-l-hot-water-extracts-show-potent-activity-in-vitro-against-covid-19-variants-including-delta.html
Article Title: Artemisia annua L. hot-water extracts show potent activity in vitro against Covid-19 variants including delta

Posted: 2021-11-05 19:00:00
Ethnopharmacological relevance: For millennia, Artemisia annua L. was used in Southeast Asia to treat "fever". This medicinal plant is effective against multiple pathogens and is used by many global communities as a source of artemisinin derivatives that are first-line drugs to treat malaria caused by Plasmodium parasites. Aim of the study: The SARS-CoV-2 (Covid-19) global pandemic has killed millions and evolved numerous variants, with delta being the most transmissible to date and causing break-through infections of vaccinated individuals. We further queried the efficacy of A. annua cultivars against new variants. Materials and methods: Using Vero E6 cells, we measured anti-SARS-CoV-2 activity of dried-leaf hot-water A. annua L. extracts of four cultivars, A3, BUR, MED, and SAM, to determine their efficacy against five infectious variants of the virus: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), and kappa (B.1.617.1). Results: In addition to being effective against the original wild type (WT) WA1, A. annua cultivars A3, BUR, MED, and SAM were also potent against all five variants. IC50 and IC90 values based on measured artemisinin content ranged from 0.3 to 8.4 μM and 1.4-25.0 μM, respectively. The IC50 and IC90 values based on dried leaf weight (DW) used to make the tea infusions ranged from 11.0 to 67.7 μg DW and 59.5-160.6 μg DW, respectively. Cell toxicity was insignificant at a leaf dry weight of ≤50 μg in the extract of any cultivar. Conclusions: Results suggest that oral consumption of A. annua hot-water extracts (tea infusions) could potentially provide a cost-effective therapy to help stave off the rapid global spread of these variants, buying time for broader implementation of vaccines. Keywords: Artemisinin; Covid-19; Delta variant; Gamma variant; Kappa variant; SARS-CoV-2.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集
7月 18, 2021 石川 栞理

COVID-19モノクローナル抗体療法は、高リスク患者に早期投与することで医療システムの負担を軽減することができるとの報告

南フロリダ大学(USF Health)とタンパ総合病院(Tampa General Hospital)が新たに発表した研究によると、モノクローナル抗体は、リスクの高い患者に早期に投与することで、 COVID-19 に関連する救急外来の受診や入院を減少させる効果があることがわかった。FDAのガイドラインに沿って使用すれば、この治療法は、パンデミックによる患者や限られた医療資源への継続的な負担を軽減することができる、と研究者らは提案している。この共同研究は、2021年6月4日にOpen Forum…